Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026
Guardant Health and its collaborators will present 25 abstracts, including five rapid oral presentations, at the ESMO Congress 2026 in Madrid on October 23-27. The presentations span methylation-based ctDNA monitoring, tissue-free MRD surveillance, and liquid biopsy research across lung, colorectal, and gastric cancers, including the FORTITUDE, PACE-LUNG, and CROWN studies.
Key figures
- Abstracts count
- 25
- Rapid oral presentations
- 5
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.